Department of Chemistry, University of Alabama at Birmingham, 901 14th Street South, Birmingham, AL 35294-1240, USA; Center for Biophysical Sciences and Engineering, University of Alabama at Birmingham, 1025 18th Street South, Birmingham, AL 35294-1240, USA.
Inserm UMR1069, Nutrition, Croissance et Cancer, Université de Tours, Faculté de médecine, 10 Boulevard Tonnellé, 37032 Tours, Cedex, France.
Bioorg Med Chem. 2018 May 15;26(9):2428-2436. doi: 10.1016/j.bmc.2018.04.003. Epub 2018 Apr 3.
Voltage-gated sodium channels (VGSC) are a well-established drug target for anti-epileptic, anti-arrhythmic and pain medications due to their presence and the important roles that they play in excitable cells. Recently, their presence has been recognized in non-excitable cells such as cancer cells and their overexpression has been shown to be associated with metastatic behavior in a variety of human cancers. The neonatal isoform of the VGSC subtype, Na1.5 (nNa1.5) is overexpressed in the highly aggressive human breast cancer cell line, MDA-MB-231. The activity of nNa1.5 is known to promote the breast cancer cell invasion in vitro and metastasis in vivo, and its expression in primary mammary tumors has been associated with metastasis and patient death. Metastasis development is responsible for the high mortality of breast cancer and currently there is no treatment available to specifically prevent or inhibit breast cancer metastasis. In the present study, a 3D-QSAR model is used to assist the development of low micromolar small molecule VGSC blockers. Using this model, we have designed, synthesized and evaluated five small molecule compounds as blockers of nNa1.5-dependent inward currents in whole-cell patch-clamp experiments in MDA-MB-231 cells. The most active compound identified from these studies blocked sodium currents by 34.9 ± 6.6% at 1 μM. This compound also inhibited the invasion of MDA-MB-231 cells by 30.3 ± 4.5% at 1 μM concentration without affecting the cell viability. The potent small molecule compounds presented here have the potential to be developed as drugs for breast cancer metastasis treatment.
电压门控钠离子通道(VGSC)是抗癫痫、抗心律失常和止痛药物的既定药物靶点,因为它们在兴奋细胞中存在且发挥着重要作用。最近,它们在非兴奋细胞(如癌细胞)中也被发现,并且它们的过表达已被证明与多种人类癌症的转移行为有关。VGSC 亚型的新生儿同工型 Na1.5(nNa1.5)在高度侵袭性的人乳腺癌细胞系 MDA-MB-231 中过表达。nNa1.5 的活性已知可促进乳腺癌细胞在体外侵袭和体内转移,其在原发性乳腺肿瘤中的表达与转移和患者死亡有关。转移的发展是导致乳腺癌高死亡率的原因,目前尚无专门用于预防或抑制乳腺癌转移的治疗方法。在本研究中,使用 3D-QSAR 模型来辅助低微摩尔小分子 VGSC 阻滞剂的开发。使用该模型,我们设计、合成并评估了五种小分子化合物作为 MDA-MB-231 细胞全细胞膜片钳实验中 nNa1.5 依赖性内向电流的阻滞剂。从这些研究中鉴定出的最活性化合物在 1µM 时可抑制钠电流 34.9±6.6%。该化合物在 1µM 浓度下还抑制 MDA-MB-231 细胞的侵袭,抑制率为 30.3±4.5%,而不影响细胞活力。这里提出的有效小分子化合物有可能被开发为治疗乳腺癌转移的药物。